EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to

empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today

that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for EURneffy (adrenaline nasal

spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh greater than 30 kg.

“The approval of EURneffy marks a major milestone as the first needle-free adrenaline treatment available in the U.K. for adults and children with

severe allergies. This innovation addresses a critical need for the many patients who may not carry, or hesitate to use, an injectable option in an

emergency,” said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma. “The innovative design of EURneffy with its small size,

temperature stability up to 50°C and longer shelf life compared to auto-injectors, encourages patients and caregivers to always carry and use

epinephrine at the first sign of symptoms related to a food or venom allergy reaction. We are pleased to receive this approval and expand availability of

our epinephrine nasal spray as part of our partnership with ALK-Abelló A/S.”

In November 2024, ARS Pharma entered into an exclusive licensing agreement with ALK-Abelló A/S (Nasdaq: ALK B), granting ALK the rights to

commercialize neffy (epinephrine nasal spray) outside the United States, including Europe (where it is marketed as EURneffy), Canada, and select

other international markets. ARS Pharma retains full commercial rights to neffy in the U.S., with no changes to its existing partnerships in Japan,

China, Australia, and New Zealand. Under the terms of the agreement, ARS Pharma received a $145 million upfront payment in 2024 and is eligible

for up to an additional $320 million in regulatory and commercial milestone payments, in addition to tiered double-digit royalties in the teens on net

sales in the licensed territories.

neffy is commercially available in the U.S. for the emergency treatment of allergic reactions, including anaphylaxis, in adults and children aged 4 years

and older who weigh at least 33 pounds (15 kg). In May 2025, ARS Pharma and ALK initiated a four-year co-promotion agreement aimed at expanding

outreach to nearly 20,000 healthcare providers, particularly pediatricians, during the critical back-to-school season, which represents a peak period for

epinephrine prescriptions.

In late June, ALK successfully launched EURneffy in Germany. Regulatory approvals for neffy in Canada (with ALK), Japan (in partnership with

Alfresa), and Australia (in partnership with CSL), are expected by the end of 2025, with commercial rollouts planned for early 2026. As well, regulatory

approval for neffy in China (in partnership with Pediatrix) is expected in 2026.

EURneffy is the trade name for neffy® (epinephrine nasal spray) in the United Kingdom.

About neffy®

weigh 33 lbs. or greater.

neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who

INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older

who weigh 33 lbs. or greater.

IMPORTANT SAFETY INFORMATION

neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes,

and can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes.

Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose

of neffy if symptoms continue or come back. Each neffy contains a single dose of epinephrine. neffy is for use in the nose only.

Use neffy right away, as soon as you notice symptoms of an allergic reaction. If symptoms continue or get worse after the first dose of neffy, a second

dose is needed. If needed, administer a second dose using a new neffy in the same nostril starting 5 minutes after the first dose. Get emergency

medical help for further treatment of the allergic emergency (anaphylaxis), if needed after using neffy.

Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your

medical conditions, especially if you have heart problems, kidney problems, low potassium in your blood, Parkinson's disease, thyroid problems, high

blood pressure, diabetes, are pregnant or plan to become pregnant, or plan to breastfeed.

Tell your healthcare provider if you take or use other nasal sprays or water pills (diuretics) or if you take medicines to treat depression, abnormal heartbeats, Parkinson's disease, heart disease, thyroid disease, medicines used in labor, and medicines to treat allergies. neffy and other medications may

affect each other, causing side effects. neffy may affect the way other medicines work, and other medicines may affect how neffy works.

neffy may cause serious side effects. If you have certain medical conditions or take certain medicines, your condition may get worse, or

you may have more or longer lasting side effects when you use neffy.

Common side effects of neffy include: nasal discomfort, headache, throat irritation, chest and nasal congestion, feeling overly excited, nervous or

anxious, nose bleed, nose pain, sneezing, runny nose, dry nose or throat, tingling sensation, including in the nose, feeling tired, dizziness, nausea,

and vomiting.

Tell your healthcare provider if you have any side effects that bother you or that do not go away after using neffy.

These are not all of the possible side effects of neffy. Call your healthcare provider for medical advice about side effects. To report side effects, contact

ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information and Patient Information for neffy.

About Type I Allergic Reactions Including Anaphylaxis

Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require

immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to

be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an

emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity

of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last

three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in

2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed

auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an

emergency.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic

reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray

indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age

and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods,

medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For

more information, visit www.ars-pharma.com.

Forward Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities

Litigation Reform Act of 1995. These statements include, but are not limited to: the belief that ARS Pharma is well positioned for sustained growth and

meaningful value creation; expected benefits from the co-promotion agreement with ALK; the extent to which ARS Pharma's efforts to reach key

prescribing pediatricians will be accelerated through the co-promotion agreement prior to the back-to-school season or thereafter; the anticipated

timing of regulatory decisions for neffy in Canada, China, Japan and Australia; the expected timing of commercial launches in the U.K.; the

needle-free profile of neffy increasing the likelihood that patients will both carry and administer epinephrine; the potential market and demand for

neffy; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ

materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “expect,” “if,”

“may,” “on track to/for,” “potential,” “plan,” “will,” “would,” and similar expressions are intended to identify forward-looking statements. These forward-

looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to

be incorrect.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and

uncertainties, which include, without limitation: potential safety and other complications from neffy; the ability to obtain and maintain regulatory

approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy; the scope,

progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay,

limit or deny coverage for neffy; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis

intramuscular injectable products; ARS Pharma’s’ ability to protect its intellectual property position; and the impact of government laws, regulations

and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the

forward-looking statements are included under the caption “Risk Factors” in ARS Pharma’s Annual Report on Form 10-K for the year ended December

31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and in ARS Pharma’s Quarterly Report on Form 10-Q for

the quarter ended March 31, 2025, filed with the SEC on May 14, 2025. These documents can also be accessed on ARS Pharma’s website at

www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab.

The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not

intend to update these forward-looking statements, except as required by law. For more information, visit www.ars-pharma.com, and follow us on

LinkedIn and X.

ARS Investor Contact:

Justin Chakma

ARS Pharmaceuticals

justinc@ars-pharma.com

ARS Media Contact:

Christy Curran

Sam Brown Inc.

615.414.8668christycurran@sambrown.com